Alinity m HR HPV
Abbott Molecular, Inc. · Decision date Sep 2, 2026
What did the FDA decide?
FDA records P230003/S019 as a supplement to PMA P230003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 2, 2026.
FDA approval order statement
replacement of an instrument part
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Sep 2, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230003/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- Decision code
- OK30
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Abbott Molecular, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230003 · Original PMA
Alinity m HR HPV
P230003/S019 received
Application receipt date recorded by FDA.
P230003/S019 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP100020/S066 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA | |
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P230003/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



